Drug Interaction Report
3 potential interactions and/or warnings found for the following 2 drugs:
- quizartinib
- Vitrakvi (larotrectinib)
Interactions between your drugs
larotrectinib quizartinib
Applies to: Vitrakvi (larotrectinib), quizartinib
Information for this minor interaction is available on the professional version.
Drug and food interactions
larotrectinib food
Applies to: Vitrakvi (larotrectinib)
Grapefruit juice can increase the blood levels of larotrectinib. This may increase the risk and/or severity of side effects such as dizziness, confusion, coordination problems, memory problems, liver problems, and tingling, numbness or burning in the hands and feet. You should avoid the consumption of grapefruit and grapefruit juice during treatment with larotrectinib. Talk to your doctor or pharmacist if you have questions on this or other medications you are prescribed. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.
Multikinase inhibitors
Therapeutic duplication
The recommended maximum number of medicines in the 'multikinase inhibitors' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'multikinase inhibitors' category:
- quizartinib
- Vitrakvi (larotrectinib)
Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Venclexta
Venclexta may be used to treat chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma ...
Vidaza
Vidaza is used to treat certain types of bone marrow cancers and blood cell disorders. Learn about ...
Ubrelvy
Ubrelvy (ubrogepant) tablets are used for the acute treatment of migraine. Includes Ubrelvy side ...
Tibsovo
Tibsovo (ivosidenib) is a once-daily oral medication that targets a specific gene mutation called ...
Ivosidenib
Ivosidenib is used for acute myeloid leukemia, biliary tract tumor, myelodysplastic syndrome
Daunorubicin
Daunorubicin is used for acute lymphocytic leukemia, acute myeloid leukemia, acute nonlymphocytic ...
Revumenib
Revumenib is used for acute lymphoblastic leukemia, acute myeloid leukemia, leukemia
Azacitidine
Azacitidine is used for acute myeloid leukemia, myelodysplastic syndrome
Cytarabine
Cytarabine is used for acute myeloid leukemia, acute nonlymphocytic leukemia, chronic myelogenous ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.